Glaucoma Candidate Takes Steps Toward FDA Approval


Latanoprostene bunod (Vesneo) demonstrated noninferiority to timolol maleate (Timoptic 5%) in pivotal Phase 3 studies.

Because latanoprostene bunod (Vesneo) demonstrated noninferiority to timolol maleate (Timoptic 5%) in pivotal Phase 3 studies, Bausch + Lomb expects to submit a new drug application to the FDA for the glaucoma treatment’s approval in mid-2015.

Previously known as BOL-303259-X and NCX 116, Vesneo is a novel nitric oxide-donating prostaglandin F2-alpha analog that was developed to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, according to Bausch + Lomb parent company, Valeant Pharmaceuticals International Inc.

The drug’s Phase 3 program included 2 separate randomized, multicenter, double-masked, parallel-group clinical studies, APOLLO and LUNAR, which were designed to compare the efficacy and safety of Vesneo to Timoptic 5%. Across a combined total of 840 patients, those treated with Vesneo experienced a reduction in mean IOP of 7.5 to 9.1 mm Hg from baseline between 2 and 12 weeks of treatment—an effect that was statistically superior to Timoptic treatment.

"The results of these studies confirm the results observed in the Phase 2b trials,” noted Robert Weinreb, MD, chairman and professor of Ophthalmology and director at the Hamilton Glaucoma Center at the University of California, San Diego, in the press release. “Vesneo effectively lowered IOP, which is critical in the management of glaucoma or ocular hypertension, and was well-tolerated."

Although there were no significant safety findings in either trial, such data from the studies will be collected for a total of up to 12 months. In the meantime, Bausch + Lomb expects to file for Vesneo’s FDA approval in the first half of 2015 and then launch the drug by the first half of 2016.

"Valeant is committed to innovation in healthcare and continues to fund important research and development programs that will bring benefits to physicians and the patients they serve," stated Valeant Chairman and CEO J. Michael Pearson in a press release. "We are pleased with the Phase 3 program top-line results and look forward to continuing to advance the Vesneo program as part of this commitment.”

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.